论文部分内容阅读
赛尼哌 (Ｚｅｎａｐａｘ)是一种通过基因合成的人 /小鼠嵌合体型单克隆抗体 ,由小鼠抗ＩＬ 2受体单克隆抗体的高变区取代人ＩｇＧ的高变区构建而成[1,2 ] 。我院从 2 0 0 0年 9月至 2 0 0 1年 3月选择 2 0例肾移植受者 ,用两剂量Ｚｅｎａｐａｘ预防肾移植术后急性排斥反应 ,取
Zenapax (Zenapax) is a human / mouse chimeric monoclonal antibody genetically synthesized from the hypervariable region of the mouse anti-IL 2 receptor monoclonal antibody to replace the hypervariable region of human IgG [ 1,2]. Twenty cases of renal transplant recipients were selected from September 2000 to March 2001 in our hospital. Two doses of Zenapax were used to prevent acute rejection after renal transplantation.